Rare Reagent Price. With respect to Rare Reagents sold by Gen-Probe to Chiron hereunder, within thirty (30) days after receipt of each shipment and invoice of Rare Reagents, Chiron shall pay to gen-probe an amount equal to one hundred twenty percent (120%) of the manufacturing cost for all rare reagents purchased by Chiron for use in manufacturing nonexclusive future clinical Diagnostic Assays under Section 4.3.4(a) above.
Appears in 2 contracts
Samples: Agreement (Gen Probe Inc), Agreement (Gen Probe Inc)
Rare Reagent Price. With respect to Rare Reagents sold by Gen-Probe to Chiron hereunder, within Within thirty (30) days after receipt of each shipment and invoice of Rare Reagents, Chiron shall pay to genGen-probe Probe an amount equal to one hundred twenty percent (120%) [***] of the manufacturing cost Manufacturing Costs for all rare reagents Rare Reagents purchased by Chiron for use in manufacturing nonexclusive future clinical Diagnostic Future Blood Screening Assays under Section 4.3.4(a3.2.4(b) above.
Appears in 2 contracts
Samples: Agreement (Gen Probe Inc), Agreement (Gen Probe Inc)
Rare Reagent Price. With respect to Rare Reagents sold by Gen-Probe to Chiron hereunder, within Within thirty (30) days after receipt of each shipment and invoice of Rare Reagents, Chiron shall pay to genGen-probe Probe an amount equal to one hundred twenty percent (120%) [***] of the manufacturing cost Manufacturing Cost for all rare reagents Rare Reagents purchased by Chiron for use in manufacturing nonexclusive future clinical Diagnostic Initial Blood Screening Assays under Section 4.3.4(a3.1.3(b) above. *** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
Appears in 2 contracts
Samples: Agreement (Gen Probe Inc), Agreement (Gen Probe Inc)
Rare Reagent Price. With respect to Rare Reagents sold by Gen-Probe to Chiron hereunder, within Within thirty (30) days after receipt of each shipment and invoice of Rare Reagents, Chiron shall pay to genGen-probe Probe an amount equal to one hundred twenty percent (120%) of the manufacturing cost Manufacturing Cost for all rare reagents Rare Reagents purchased by Chiron for use in manufacturing nonexclusive future clinical Initial Clinical Diagnostic Assays under Section 4.3.4(a4.1.3(b) above.
Appears in 2 contracts
Samples: Agreement (Gen Probe Inc), Agreement (Gen Probe Inc)
Rare Reagent Price. With respect to Rare Reagents manufactured sold by Gen-Probe to Chiron hereunder, within thirty (30) days after receipt of each shipment and invoice of Rare Reagents, Chiron shall pay to genGen-probe Probe an amount equal to one hundred twenty percent (120%) of the manufacturing cost Manufacturing Cost for all rare reagents Rare Reagents purchased by Chiron for use in manufacturing nonexclusive future clinical Exclusive Future Clinical Diagnostic Assays under Section 4.3.4(aSections 4.2.4(b) and 4.2.4(c) above.
Appears in 2 contracts
Samples: Agreement (Gen Probe Inc), Agreement (Gen Probe Inc)
Rare Reagent Price. With respect to Rare Reagents sold by Gen-Probe to Chiron hereunder, within Within thirty (30) days after receipt of each shipment and invoice of Rare Reagents, Chiron shall pay to genGen-probe Probe an amount equal to one hundred twenty percent (120%) [CONFIDENTIAL TREATMENT REQUESTED] of the manufacturing cost Manufacturing Costs for all rare reagents Rare Reagents purchased by Chiron for use in manufacturing nonexclusive future clinical Diagnostic Future Blood Screening Assays under Section 4.3.4(a3.2.4(b) above.
Appears in 1 contract
Rare Reagent Price. With respect to Rare Reagents sold by Gen-Probe to Chiron hereunder, within Within thirty (30) days after receipt of each shipment and invoice of Rare Reagents, Chiron shall pay to genGen-probe Probe an amount equal to one hundred twenty percent (120%) [CONFIDENTIAL TREATMENT REQUESTED] of the manufacturing cost Manufacturing Cost for all rare reagents Rare Reagents purchased by Chiron for use in manufacturing nonexclusive future clinical Diagnostic Initial Blood Screening Assays under Section 4.3.4(a3.1.3(b) above.
Appears in 1 contract